A Study of Gantenerumab in Participants With Prodromal Alzheimer’s Disease
Condition(s):Alzheimer’s DiseaseLast Updated:December 13, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Alzheimer’s DiseaseLast Updated:December 13, 2021Completed
Condition(s):AsthmaLast Updated:December 29, 2011Completed
Condition(s):HypertensionLast Updated:July 21, 2009Completed
Condition(s):Alzheimer DiseaseLast Updated:June 10, 2016Terminated
Condition(s):Chronic Fatigue SyndromesLast Updated:March 17, 2021Unknown status
Condition(s):Lung CancerLast Updated:November 25, 2013Completed
Condition(s):Autism Spectrum DisorderLast Updated:May 24, 2017Completed
Condition(s):Memory Disorders, Age-Related; Retention Disorders, CognitiveLast Updated:January 15, 2019Completed
Condition(s):Hyperglycemia, Postprandial; Overweight and Obesity; Diabetes Mellitus RiskLast Updated:April 28, 2021Completed
Condition(s):Diffuse Hemispheric Glioma, H3 G34-MutantLast Updated:July 7, 2023Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.